TITLE:
Role of Trimetazidine in Coronary Artery Bypass Graft Surgery
AUTHORS:
Gerez Fernandes Martins, Gerez Martins
KEYWORDS:
Ischemia-Reperfusion Injury, Oxidative Stress, Inflammation, Trimetazidine, Coronary Artery Bypass Graft
JOURNAL NAME:
World Journal of Cardiovascular Surgery,
Vol.7 No.7,
July
26,
2017
ABSTRACT: Trimetazidine is a drug
that has been used to reduce the damage of reperfusion injury, which is a mechanism of
oxidative aggression that occurs in coronary syndromes, angioplasty procedures,
as well as in cardiovascular surgeries. Seeking to improve
myocardial protection during procedures that involve reperfusion, attention was
recently turned to research on cytoprotective drugs which act on segments of
cellular metabolism, used in isolation or combined to reduce or prevent damage
to the cardiac cell. The aim of this review is to objectively evaluate the
effects of the drug trimetazidine (TMZ) on ischemia-reperfusion
injury in coronary artery bypass graft surgery by reviewing all known studies
from recent years.